Cargando…
Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evid...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801606/ https://www.ncbi.nlm.nih.gov/pubmed/35111690 http://dx.doi.org/10.3389/fcimb.2021.733348 |
_version_ | 1784642498934603776 |
---|---|
author | Huang, Yan Gan, Qinyi Lai, Rongtao Wang, Weijing Guo, Simin Sheng, Zike Chen, Lu Guo, Qing Cai, Wei Wang, Hui Zhao, Gangde Cao, Zhujun Xie, Qing |
author_facet | Huang, Yan Gan, Qinyi Lai, Rongtao Wang, Weijing Guo, Simin Sheng, Zike Chen, Lu Guo, Qing Cai, Wei Wang, Hui Zhao, Gangde Cao, Zhujun Xie, Qing |
author_sort | Huang, Yan |
collection | PubMed |
description | BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evidence of the fibrotic effect of NAFLD or NASH in chronic hepatitis B virus (HBV) infection remains lacking. We aimed to reveal the influence of concurrent histologically proven fatty liver diseases in fibrogenesis with chronic HBV infection. METHODS: We performed a retrospective cross-sectional study on a liver biopsy population of CHB patients without excessive alcohol intake to evaluate the prevalence of concurrent histologically proven NAFLD or NASH according to the fatty liver inhibition of progression (FLIP) algorithm and its association with the liver fibrosis stage. RESULTS: Among 1,081 CHB patients, concurrent NAFLD was found in 404 patients (37.4%), among whom 24.0% (97/404) have NASH. The presence of NASH was an independent predictor of significant fibrosis (odds ratio (OR), 2.53; 95% CI, 1.52–4.21; p < 0.001) and severe fibrosis (OR, 1.83; 95% CI, 1.09–3.09; p = 0.023) in all patients, as well as in patients with normal alanine aminotransferase (ALT) (predicting significant fibrosis, OR, 2.86, 95% CI, 1.34–6.10; p = 0.007). The presence of lobular inflammation (p < 0.001) or presence of cytological ballooning (p < 0.001), rather than presence of steatosis (p = 0.419), was related with severity of fibrosis in Spearman’s correlation analysis. CONCLUSIONS: Concurrent NAFLD is common in CHB patients, and NASH is an independent risk factor potentiating significant fibrosis by 2.53-fold and severe fibrosis by 1.83-fold. While coping with chronic HBV infection, routine assessment of co-existing NAFLD or NASH is also important. |
format | Online Article Text |
id | pubmed-8801606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88016062022-02-01 Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients Huang, Yan Gan, Qinyi Lai, Rongtao Wang, Weijing Guo, Simin Sheng, Zike Chen, Lu Guo, Qing Cai, Wei Wang, Hui Zhao, Gangde Cao, Zhujun Xie, Qing Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evidence of the fibrotic effect of NAFLD or NASH in chronic hepatitis B virus (HBV) infection remains lacking. We aimed to reveal the influence of concurrent histologically proven fatty liver diseases in fibrogenesis with chronic HBV infection. METHODS: We performed a retrospective cross-sectional study on a liver biopsy population of CHB patients without excessive alcohol intake to evaluate the prevalence of concurrent histologically proven NAFLD or NASH according to the fatty liver inhibition of progression (FLIP) algorithm and its association with the liver fibrosis stage. RESULTS: Among 1,081 CHB patients, concurrent NAFLD was found in 404 patients (37.4%), among whom 24.0% (97/404) have NASH. The presence of NASH was an independent predictor of significant fibrosis (odds ratio (OR), 2.53; 95% CI, 1.52–4.21; p < 0.001) and severe fibrosis (OR, 1.83; 95% CI, 1.09–3.09; p = 0.023) in all patients, as well as in patients with normal alanine aminotransferase (ALT) (predicting significant fibrosis, OR, 2.86, 95% CI, 1.34–6.10; p = 0.007). The presence of lobular inflammation (p < 0.001) or presence of cytological ballooning (p < 0.001), rather than presence of steatosis (p = 0.419), was related with severity of fibrosis in Spearman’s correlation analysis. CONCLUSIONS: Concurrent NAFLD is common in CHB patients, and NASH is an independent risk factor potentiating significant fibrosis by 2.53-fold and severe fibrosis by 1.83-fold. While coping with chronic HBV infection, routine assessment of co-existing NAFLD or NASH is also important. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801606/ /pubmed/35111690 http://dx.doi.org/10.3389/fcimb.2021.733348 Text en Copyright © 2022 Huang, Gan, Lai, Wang, Guo, Sheng, Chen, Guo, Cai, Wang, Zhao, Cao and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Huang, Yan Gan, Qinyi Lai, Rongtao Wang, Weijing Guo, Simin Sheng, Zike Chen, Lu Guo, Qing Cai, Wei Wang, Hui Zhao, Gangde Cao, Zhujun Xie, Qing Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients |
title | Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients |
title_full | Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients |
title_fullStr | Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients |
title_full_unstemmed | Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients |
title_short | Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients |
title_sort | application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis b patients |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801606/ https://www.ncbi.nlm.nih.gov/pubmed/35111690 http://dx.doi.org/10.3389/fcimb.2021.733348 |
work_keys_str_mv | AT huangyan applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT ganqinyi applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT lairongtao applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT wangweijing applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT guosimin applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT shengzike applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT chenlu applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT guoqing applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT caiwei applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT wanghui applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT zhaogangde applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT caozhujun applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients AT xieqing applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients |